Biogen has announced new clinical trial data that demonstrates the benefits its spinal muscular atrophy (SMA) therapy Spinraza offers among paediatric patients.
A new analysis from the phase III ENDEAR study has shown that Spinraza may improve motor function outcomes in infants and children with SMA, with patients who initiated treatment earlier in the disease experiencing greater benefits and functional improvements.
“Biogen has presented new clinical data showing the effectiveness of Spinraza in treating infants and children with spinal muscular atrophy.“
Data from this study also supported the effectiveness of a dosing regimen of four loading doses in the first two months, followed by additional administrations of Spinraza every four months thereafter.
Additionally, the company has reported findings from the phase II study EMBRACE, showing greater motor milestone achievement in infants and children treated with Spinraza compared to those who were untreated.
Dr Alfred Sandrock, executive vice-president and chief medical officer at Biogen, said: "These studies contribute to a growing body of evidence that Spinraza can make a meaningful difference in the lives of people with SMA regardless of their age or stage of the disease."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical